Annual Drug Patent Expirations for NAMZARIC
Namzaric is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug and three Paragraph IV challenges.
Drug patent litigation for NAMZARIC.
This drug has fifty-five patent family members in eighteen countries.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. One supplier is listed for this compound. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
